NM_000742.4(CHRNA2):c.1151C>T (p.Pro384Leu) AND Autosomal dominant nocturnal frontal lobe epilepsy

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Sep 22, 2019
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV001234180.5

Allele description [Variation Report for NM_000742.4(CHRNA2):c.1151C>T (p.Pro384Leu)]

NM_000742.4(CHRNA2):c.1151C>T (p.Pro384Leu)

Gene:

CHRNA2:cholinergic receptor nicotinic alpha 2 subunit [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

8p21.2

Genomic location:

Preferred name:

NM_000742.4(CHRNA2):c.1151C>T (p.Pro384Leu)

HGVS:

NC_000008.11:g.27463292G>A
NG_015827.1:g.21005C>T
NM_000742.4:c.1151C>TMANE SELECT
NM_001282455.2:c.1106C>T
NM_001347705.2:c.674C>T
NM_001347706.2:c.674C>T
NM_001347707.2:c.557C>T
NM_001347708.2:c.557C>T
NP_000733.2:p.Pro384Leu
NP_001269384.1:p.Pro369Leu
NP_001334634.1:p.Pro225Leu
NP_001334635.1:p.Pro225Leu
NP_001334636.1:p.Pro186Leu
NP_001334637.1:p.Pro186Leu
NC_000008.10:g.27320809G>A
NM_000742.3:c.1151C>T

Protein change:

P186L

Links:

dbSNP: rs777510962

NCBI 1000 Genomes Browser:

rs777510962

Molecular consequence:

NM_000742.4:c.1151C>T - missense variant - [Sequence Ontology: SO:0001583]
NM_001282455.2:c.1106C>T - missense variant - [Sequence Ontology: SO:0001583]
NM_001347705.2:c.674C>T - missense variant - [Sequence Ontology: SO:0001583]
NM_001347706.2:c.674C>T - missense variant - [Sequence Ontology: SO:0001583]
NM_001347707.2:c.557C>T - missense variant - [Sequence Ontology: SO:0001583]
NM_001347708.2:c.557C>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
Identifiers:: MONDO: MONDO:0020300; MedGen: C3696898

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV001406812	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Sep 22, 2019)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV001406812

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Sep 22, 2019)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001406812.4

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The leucine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with CHRNA2-related conditions. This variant is present in population databases (rs777510962, ExAC 0.002%). This sequence change replaces proline with leucine at codon 384 of the CHRNA2 protein (p.Pro384Leu). The proline residue is weakly conserved and there is a moderate physicochemical difference between proline and leucine.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine